Merus (MRUS) Company Report

Genmab A/S has successfully completed its tender offer to acquire Merus N.V. at $97 per share, with over 94% of shares tendered.
The acquisition adds petosemtamab, Merus's lead late-stage oncology drug, to Genmab's portfolio, which is projected to launch in 2027 and potentially generate over $1 billion in annual sales by 2029.
This deal is anticipated to be accretive to Genmab’s EBITDA by the end of 2029.
Jan van de Winkel has been appointed as the CEO of Merus following the acquisition.

Dec 12, 2025, 7:00 AM

Merus N.V. shareholders approve takeover-related proposals and new directors

MRUS

M&A

Takeover Bid

Board Change

Merus N.V. shareholders held an Extraordinary General Meeting on December 9, 2025, to vote on proposals related to the takeover bid by Genmab Holding II B.V..
Shareholders approved the Back-End Transactions, including a statutory merger, which are part of the $97.00 per Common Share in cash offer from Genmab Holding II B.V..
The offer to purchase all common shares for $97.00 per share in cash is scheduled to expire on December 11, 2025, at 5:00 p.m. New York City time.
The EGM also approved the appointment of Greg Mueller, Anthony Pagano, and Martine van Vugt, Ph.D. as non-executive directors, effective upon the offer's consummation.

Dec 9, 2025, 9:00 PM

Merus Highlights Clinical Pipeline Progress and Strong Financial Position

MRUS

Product Launch

New Projects/Investments

Guidance Update

Merus's lead product candidate, Petosemtamab, is advancing with Phase 3 trials enrolling for recurrent/metastatic head and neck squamous cell cancer (r/m HNSCC) and initial interim data showing robust antitumor activity in metastatic colorectal cancer (mCRC). Topline readouts for one or both HNSCC Phase 3 trials are expected in 2026.
The company's first product, Bizengri® (zenocutuzumab), has received accelerated approval from the U.S. FDA for NRG1+ pancreatic adenocarcinoma and non-small cell lung cancer (NSCLC).
Merus reported a strong cash position of $817 million in cash and cash equivalents, which is expected to fund the company at least into 2028.
The clinical pipeline also features MCLA-129, which has demonstrated strong clinical activity in EGFRm NSCLC and METex14 NSCLC, with a 2L+ EGFRm NSCLC combination with chemotherapy enrolling.

Oct 31, 2025, 2:00 PM

Merus N.V. Foundation Supports Genmab Acquisition

MRUS

M&A

Takeover Bid

Merus N.V. and Stichting Continuïteit Merus entered into a Foundation Support Agreement on September 29, 2025.
The Foundation supports the proposed acquisition of Merus by Genmab, believing the transactions do not threaten the interests of the Company, its businesses, or its stakeholders.
Merus's Board of Directors has unanimously approved the transaction, determining it to be in the best interests of the Company and its stakeholders, and recommends shareholders accept the offer.
Genmab intends to acquire all shares of Merus for $97.00 per share in an all-cash transaction, representing a total value of approximately $8.0 billion.
The tender offer is anticipated to close by early in the first quarter of 2026.

Sep 29, 2025, 12:30 PM

Genmab Nears $5.2B Merus Acquisition

MRUS

M&A

Takeover Bid

Danish biotechnology company Genmab is in advanced acquisition talks to acquire Dutch biotech firm Merus, valued at approximately $5.2 billion.
Merus's market value has surged over 60% this year due to promising clinical trial results of its bispecific antibody petosemtamab, which showed a 63% response rate in head and neck cancer treatments.
Genmab, with a market capitalization near $18.5 billion, aims to strengthen its oncology pipeline through this acquisition, which would be its largest ever.
Despite strong liquidity and low debt levels, Merus has faced operational challenges, including a revenue decline of 23.8% over the past three years and significant negative operating (-619.33%) and net margins (-685.64%).
The completion of the Genmab deal remains uncertain, despite multiple takeover offers for Merus and potential imminent announcement.

Sep 28, 2025, 10:18 PM

Get instant answers from SEC filings, earnings calls & more